Innovent Biologics, Inc. a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany for the combination therapy of IBI351 (GFH925) with cetuximab (ERBITUX) as a potential treatment for NSCLC patients harboring KRASG12C mutation in a Phase 1b clinical trial in China. Under...